GSK Most Likely To Buy Pfizer's Consumer Business – Is It A Step In Wrong Direction?
UPDATE: SOON AFTER PUBLICATION OF THIS ARTICLE GSK ANNOUNCED IT HAD WITHDRAWN FROM THE BIDDING FOR PFIZER'S CONSUMER HEALTH BUSINESS. GSK looks likely to be the top bidder for Pfizer's consumer health business, with an offer announcement expected soon – but are more OTC products the answer to the UK major's longer-term sustainability and growth issues?
You may also be interested in...
Pfizer continues to review options for its consumer business, though analysts say a spin-off makes most sense. During its fourth-quarter earnings call, firm reported the division's US sales slumped 9% but 12% growth in international markets buoyed the worldwide results.
UK pharma giant GlaxoSmithKline has nabbed a high-profile figure from Google's Calico to head up its research efforts. Barron's oncology pedigree from his time at Roche suggests that cancer is again a core area for GSK.
In her first address as CEO, Emma Walmsley has shocked the market with a long list of changes for GSK, including a total makeover of the group's pharma unit. As a result, more than 30 R&D programs will be getting the axe and a 2011 commercialization partnership with Johnson & Johnson is on its way to the gallows.